BIO KOREA 2020 International Convention to Go Virtual
BIO KOREA 2020 International Convention, where global bio experts correspond, is shifting to an online-only event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200424005107/en/
BIO KOREA 2020 will be held as an online convention from May 18 09:00 to 23 18:00. BIO KOREA Organizing Committee has taken its final measures to execute a full digitalization of the event considering the health and safety of its participants and prevention of the further spread of COVID-19 ultimate importance above all other matters concerned. Under the main theme “A New Paradigm in the Age of Data Science”, BIO KOREA 2020 will be held as an online convention, maintaining its five main programs consisting of Conference, Business Forum, Exhibition, Invest Fair, and Job Fair. You can participate on BIO KOREA 2020 Official Website: www.biokorea.org. (Graphic: Business Wire)
BIO KOREA Organizing Committee has taken its final measures to execute a full digitalization of the event considering the health and safety of its participants and prevention of the further spread of Coronavirus (COVID-19) ultimate importance above all other matters concerned. In place of hosting an in-person format in Seoul, it will digitally take place over the entire week of May 18 – 23, 2020.
Under the main theme “A New Paradigm in the Age of Data Science”, BIO KOREA 2020 will be held as an online convention, maintaining its five main programs consisting of Conference, Business Forum (Partnering), Exhibition, Invest Fair, and Job Fair.
BIO KOREA 2020 Online Convention – from e-Conference, Online Meeting, and Virtual Exhibition
Regardless of the current outbreak of COVID-19, BIO KOREA 2020 will continue to cater for its participants to its best means. As the five main programs of BIO KOREA (Conference, Business Forum (Partnering), Exhibition, Invest Fair, and Job Fair) are delivered online, its participants can partake in the convention with safety and convenience. Moreover, this pioneering move will greatly enhance the efficiency in terms of time and effort put in by the presenters and all other participants for the preparation and operation of BIO KOREA 2020.
The five main programs of BIO KOREA 2020 will create an arena where in-depth academic knowledge and innovative entrepreneurial ideas are exchanged by way of e-Conference and Online Business Forum with partnering (Online Meeting). Those gems of knowledge and innovation will then be elaborated and visualized by numerous leading bio-companies around the globe in Virtual Exhibition. Not only that, BIO KOREA 2020’s Invest Fair and Job Fair will provide invaluable opportunities for general investors and the public to directly participate into the global bio industry.
BIO KOREA Organizing Committee stated that it is spurring towards preparing BIO KOREA 2020 as an online convention determined to support the information exchange of the bio industry. In addition to its advanced implementation including the operation of VR Zone and Live streaming, the Committee aims to conduct a safe and successful delivery of BIO KOREA 2020 as an online convention, turning the global crisis into opportunity.
BIO KOREA is a place of practical business correspondence as well as international information and technology exchange, invigorating the bio industry. In its 15th year of bringing together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs, BIO KOREA had been providing abundant opportunities to assure competitive edges within the convergence industry centered around biotechnology.
For more information, visit BIO KOREA’s Official Website: www.biokorea.org and https://www.youtube.com/watch?v=7tYarlZEL0A&feature=youtu.be.
BIO KOREA Organizing Committee
Suyeon Choi, Researcher
+82-1661-0810 (O! BIO)
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 20205.12.2020 16:00:00 CET | Press release
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin for relapsed/refractory T-Cell Lymphoma patients at the upcoming 62nd American Society of Hematology (ASH) annual meeting and exposition, to be held virtually from December 5 – 8, 2020. The poster presentation at ASH, 2020 includes interim data from a multi-center, open label, Phase I/II study in patients with T cell lymphoma (NCT03770000) with the objective of determining the MTD/optimal dose of Tenalisib given in combination with Romidepsin and assessing the preliminary efficacy of the combination. No dose limiting toxicities were reported and Tenalisib 800 mg BID plus Romidepsin 14 mg/m2 was determined to be the maximum tolerated dose for the expansion cohorts. Overall, the Tenalisib and Romidepsin combination was well tolerated across all patients (N=33) with no unexpected adverse eve
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX ® ▼ (daratumumab) Subcutaneous Formulation Regimen After First or Subsequent Relapse in Multiple Myeloma4.12.2020 20:52:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of the Phase 3 APOLLO study showing that the addition of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation to pomalidomide and dexamethasone (D-Pd) significantly reduced the risk of progression or death by 37 percent, compared to Pd alone in patients with multiple myeloma (MM) after the first or subsequent relapse of disease.1 The APOLLO results, which will be presented on Sunday, December 6 at 9:00 p.m. CET during the American Society of Hematology (ASH) 2020 Annual Meeting and featured in the ASH press briefing (Abstract #112), add to the body of evidence supporting treatment with daratumumab SC-based regimens for patients with relapsed MM. These data were the basis for recent regulatory submissions in Europe and the United States (U.S.) seeking approval for daratumumab SC in combination with Pd for the treatment of patients with relapsed or refractory MM, with two or more prior lines of therapy, includi
Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World4.12.2020 17:36:00 CET | Press release
Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors. Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global healthcare crisis in more than a century. 2020 was an opportunity for the world to “test drive the future” and make way for growth as the pandemic ebbs. The tailwinds for 2021 are underappreciated: our financial system is strong, government actions to protect individuals and businesses have been effective, technological
Takashi Nagao Appointed President and Chief Executive Officer of Medicago4.12.2020 17:00:00 CET | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today. Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond
WorldRemit Leads the Way Offering a USD Payout Option in Nigeria4.12.2020 16:46:00 CET | Press release
WorldRemit, a leading digital cross-border payments business has announced that its customers in Nigeria can now receive remittances in foreign currency (USD) through its cash pick up providers. Following the announcement of the Central Bank of Nigeria (CBN) a day before, WorldRemit quickly adapted to the new requirements making it the first digital service to offer its customers worldwide the option of cash pickup in USD in Nigeria. WorldRemit enables Nigerians in over 50 countries around the world to support their family and friends in Nigeria. The decision by the Central Bank of Nigeria (CBN) to allow international money transfers to be paid in foreign currency, is aimed at providing increased liquidity in the foreign exchange market. The bank explained that the new regulation is part of its efforts to liberalize, simplify and improve the receipt and administration of diaspora remittances into Nigeria. Gbenga Okejimi, Country Manager, Nigeria and Ghana, at WorldRemit, said:“ We are
PPC Upgraded to ‘B’ with ‘Stable’ Outlook by S&P4.12.2020 15:16:00 CET | Press release
In its annual research update released on 27 November 2020, S&P upgraded PPC’s stand-alone credit profile (SACP) upward by two notches to ‘B’ from ‘CCC+’, resulting in an overall upgrade of the long-term credit rating of PPC to ‘B’ from ‘B-‘. According to S&P the two notch upgrade in PPC’s standalone corporate rating confirms that the Company’s strategic repositioning and the improved Greek energy market fundamentals have transformed its competitive position, reducing past concerns over its liquidity and long-term sustainability. The ‘Stable’ outlook underscores S&P’s expectation that PPC will continue to deliver on its transformation plan, with solid liquidity and improved margins. PPC’s strategic plan to convert its generation mix toward lower carbon dioxide (CO2) emissions improve its fleet competitiveness and long-term prospects. As mentioned in their report, S&P expects a substantial increase in EBITDA and improvement in credit metrics on the back of higher profitability as PPC ac
Chengdu Launches Online Exhibition of History and Culture to Enhance Cultural Ties With European Countries4.12.2020 13:17:00 CET | Press release
The launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition was held by the Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office on 24 November. The event, along with the unveiling ceremony of Chengdu Chronicles Culture Overseas (Europe) Exchange Cooperation, were witnessed by distinguished guests in many European countries including the Netherlands, Germany and Belgium through video and online connections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005278/en/ On November 24, Gao Zhigang (center), Director of Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office, and other guests attend the launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition. (Photo: Business Wire) Chengdu History and Culture Overseas Virtual Exhibition will also be launched at major foreign media platforms for audiences all over the world. Gao ZhiGang, Director of Che
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom